9,739 Shares in Sanofi (NASDAQ:SNY) Acquired by Brucke Financial Inc.

Brucke Financial Inc. purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 9,739 shares of the company's stock, valued at approximately $470,000.

A number of other large investors have also bought and sold shares of the stock. Synergy Asset Management LLC bought a new position in shares of Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the fourth quarter worth about $31,000. Bessemer Group Inc. lifted its stake in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $44,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 5.6%

Shares of SNY stock traded down $2.95 during midday trading on Friday, reaching $49.40. 4,670,469 shares of the stock were exchanged, compared to its average volume of 2,401,705. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The firm has a market cap of $121.15 billion, a PE ratio of 19.84, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The company's 50 day moving average is $52.25 and its two-hundred day moving average is $51.90.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm's quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.78 EPS. On average, equities research analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Finally, Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.